The results demonstrated that the combination treatment produced a significantly synergistic inhibitory effect on tumor cell growth, especially on SMAD4-defficient/gemcitabine-resistant AsPC-1 cells or xenografted tumors (Figs. 2, 5). The gene discussed is SMAD4; the disease is neoplasm.